Active Biotech AB
ACTI.STDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
ABR-217620/naptumomab estafenatox
Renal Cell Carcinoma
tasquinimod
Prostate Cancer
paquinimod (ABR-215757)
Systemic Lupus Erythematosus
paquinimod
Systemic Sclerosis
ABR-215050, tasquinimod
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABR-217620/naptumomab estafenatox | Phase 3 | Renal Cell Carcinoma | - | - |
tasquinimod | Phase 3 | Prostate Cancer | - | - |
paquinimod (ABR-215757) | Phase 2 | Systemic Lupus Erythematosus | - | - |
paquinimod | Phase 2 | Systemic Sclerosis | - | - |
ABR-215050, tasquinimod | Phase 2 | Prostate Cancer | - | - |
Frequently asked questions
What is in Active Biotech AB's drug pipeline?→
CatalystAlert tracks 5 drug candidates in Active Biotech AB's (ACTI.ST) pipeline across Phase 3, Phase 2. Its lead program is ABR-217620/naptumomab estafenatox (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Active Biotech AB's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Active Biotech AB (ACTI.ST) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ACTI.ST biotech catalysts?→
Add ACTI.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Active Biotech AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.